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cell carcinoma after ipilimumab exposure
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Ipilimumab, an immune checkpoint inhibitor, is
approved for the treatment of advanced melanoma.
Its potential activity in keratinocytic cancers, how-
ever, is not well known. We present a case of a man
in his 60s with advanced basal cell carcinoma (BCC)
that regressed after incidental exposure to ipilimu-
mab to treat the patient’s concurrent metastatic
melanoma.
CASE REPORT
A man in his 60s presented to the dermatology
clinic with a 40-year history of a slowly growing
plaque behind his left ear that had recently auto
amputated the pinna. He had not previously sought
medical care, and on physical examination, there
was a 13-cm ulcerated plaque around the external
auditory meatus. A biopsy found nodular BCC, and
magnetic resonance imaging (MRI) found infiltration
of the 7th cranial nerve, parotid gland, masseter
muscle, and left pterygoid bone with enhancement
surrounding the left mandibular condyle and within
the infratemporal fossa. The patient declined surgical
treatment and started vismodegib at 150 mg daily
with excellent clinical response with regression to
2-cm longest diameter after 1 year of treatment.
However, a biopsy of the remaining tumor found
residual BCC.
At this time, a new 4-mm erythematous papule at
least 2 cm removed from the residual BCC was noted
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hool of Medicine, Department of Dermatology, 450photographic documentation. A biopsy of this lesion
found an amelanotic nodular melanoma with
Breslow depth to 2.75 mm, no ulceration, and a
mitotic index of 5 per square millimeter. The patient
was not considered a good candidate for sentinel
lymph node biopsy because of extensive scarring
around the melanoma owing to BCC regression
while on vismodegib. He underwent wide local
excision with 1-cm margins that that showed
negative margins on pathologic analysis.
The patient did not return for recommended
routine skin cancer surveillance until 14 months
later, at which time there was clinically visible
recurrence of his melanoma at the same site and
increased growth in his adjacent BCC to 93 8 cm, as
he had not been taking his vismodegib. A 1-cm
nodule was visible in the location of his prior
melanoma (Fig 1, A, box), confirmed to be the
same nodular melanoma histology on biopsy
(Fig 1, B, single arrow) and confirmed by S100
staining (Fig 1, C ). The BCC had also regrown to
abut themelanoma (Fig 1,B, double arrow). Positron
emission tomographyecomputed tomography and
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Fig 1. A, Recurrent nodular melanoma (dashed box) adjacent to advanced BCC (bracket)
before ipilimumab therapy. B, Histolopathologic analysis of the nodule shows amelanotic
nodular melanoma adjacent to BCC. Melanoma cells (double arrows) consisting of atypical
epithelioid and spindled cells abut the BCC cells (single arrow) indicated by palisading
basaloid cells with artifactual clefting. C, S100 positivity on immunohistochemical analysis
highlights spindled cells, supporting melanoma histology (double arrows). BCC does not
display S100 positivity (single arrow) (1003 magnification, hematoxylin and eosin stain).
D, After 8 weeks of ipilimumab exposure, the melanoma showed increased ulceration and
growth (dashed box); however, the BCC had regressed with granulation tissue (bracket) filling
the prior BCC ulcer bed and re-epithelialization (white arrow). Black arrow indicates site of
biopsy that showed granulation tissue and no residual BCC. (B and C, Hematoxylin-eosin stain;
original magnifications: B, 340; C, 3100.)
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to be melanoma metastases.
The patient’s melanoma was negative for the
BRAF V600E mutation; therefore, he was started on
ipilimumab at 3 mg/kg every 3 weeks. Although we
considered concurrent therapy with vismodegib totreat the adjacent BCC, the lack of data on its safety
and tolerability with ipilimumab led us to not
reintroduce this treatment.
After 6 weeks of ipilimumab, the patient reported
mild memory loss and difficulty with balance. An
MRI scan of the brain found melanoma disease
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addition, the patient’s lactate dehydrogenase level
increased from 43 U/L before ipilimumab initiation
to 2,864 U/L. After 8 weeks of ipilimumab therapy,
on clinical examination, his melanoma had unfortu-
nately grown visibly (Fig 1, D, dashed red box).
We were surprised to observe that the adjacent
BCC had decreased in size from 9 3 8 cm before
ipilimumab to 5 3 7 cm after ipilimumab, with
significant granulation tissue replacing the previous
BCC ulcer (Fig 1, D). Although it was not feasible to
sample the entire granulation tissue area for residual
BCC, we did perform a 4-mm biopsy by punch
technique to confirm granulation tissue and lack of
BCC (Fig 1, D, arrow). Unfortunately, the patient
passed away 2 weeks later from progressive central
nervous system deterioration caused by metastatic
melanoma. Nevertheless, the differential response of
these 2 tumors types in this case offered a rare
glimpse into the potential for systemic immuno-
therapy for nonmelanoma skin cancers.
DISCUSSION
To our knowledge, there are no reports of BCCs
treated with immune checkpoint inhibitors. We
describe a case of advanced BCC regressing in the
setting of ipilimumab treatment for treatment of a
concurrent metastatic melanoma. This case of
incidental exposure and regression of an advanced
BCC to ipilimumab suggests that ipilimumab
may have activity against BCCs. Ipilimumab bindscytotoxic T-lymphocyte antigene4 (CTLA4) and
promotes T-cell recognition of tumors such as
melanoma1 and nonesmall cell lung cancer.2 BCCs
are well known to respond to immunotherapy in the
form of the topical toll-like receptore7 agonist,3
imiquimod, although the pathways stimulated by
ipilimumab and imiquimod are likely distinct.
However, emerging evidence shows that the
injectable toll-like receptore7/8 agonist, 3M-052,
potentiates the checkpoint blockade therapy of
anti-CTLA4 antibodies and can augment antitumor
effects of anti-CTLA4 antibodies.4 Our observations
suggest that ipilimumab may have activity against
BCC, and clinical trials utilizing this drug either alone
or in combination with other therapies are needed to
confirm this observation.
The authors are indebted to Robert LeBlanc, MD, for
assistance with pathologic interpretation.
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